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Abstract DNA repair by homologous recombination is one
of the main processes of DNA double strand breaks repair.
In the present work we performed a case-control study (304
cases and 319 controls) to check an association between the
genotypes of the c.-61 G>T and the g.38922 C>G poly-
morphisms of the RAD51 gene and the g.96267 A>C and
the g.85394 A>G polymorphisms of the BLM gene and
breast cancer occurrence. Genotypes were determined in
DNA from peripheral blood by PCR-RLFP and by PCR-
CTPP. We observed an association between breast cancer
occurrence and the T/G genotype (OR 4.41) of the c.-61
G>T-RAD51 polymorphism, the A/A genotype (OR 1.69)
of the g.85394 A>G-BLM polymorphism and the A/A
genotype (OR 2.49) of the g.96267 A>C-BLM polymor-
phism. Moreover, we demonstrated a correlation between
intra- and intergenes genotypes combinations and breast
cancer occurrence. We found a correlation between proges-
terone receptor expression and the T/G genotype (OR 0.57)
of the c.-61 G>T- RAD51 polymorphism. We also found a
correlation between the T/G genotype (OR 1.86) and the
T/T genotype (OR 0.56) of the c.-61 G>T- RAD51 poly-
morphism and the lymph node metastasis. We showed an
association between the A/A genotype (OR 2.45) and the
A/C genotype (OR 0.41) of the g.96267 A>C-BLM poly-
morphism and G3 grade of tumor. Our results suggest that
the variability of the RAD51 and BLM genes may play a
role in breast cancer occurrence. This role may be under-
lined by a common interaction between these genes.
Keywords Breast cancer .Genepolymorphism .BLMgene .
RAD51 gene . DNA double-strand breaks
Introduction
Breast cancer is one of the major causes of cancer death
among women in the world. Progress in many fields of
science has enabled to understand the mechanism of carci-
nogenesis in breast, but so far there has not been found any
clear reason of breast cancer. Two main groups of breast
cancer risk factors are genetic and environmental ones,
among which the most important are age and breast cancer
occurrence in the first and/or second step relatives. In this
case, particularly important are mutations in two high pen-
etrance genes BRCA1 and BRCA2 [1, 2], which are associ-
ated with the processes of DNA double strand breaks
(DSBs) repair. A number of studies show link between
hereditary as well as sporadic breast cancer and genetic
instability caused by DSBs [3–6]. DSBs can be repaired
by nonhomologous end-joining (NHEJ) [7], homologous
recombination repair (HRR) [8] and single-strand annealing
(SSA) [9]. However, HRR has been found to be a key
pathway in human cells for the repair of DSBs [10]. DNA
repair by homologous recombination is particularly impor-
tant during and following DNA replication, when a sister
chromatid is present as a template for repair. In eukaryotes,
the central homologous recombination protein is RAD51
which catalyses strand transfer between a broken sequence
and its undamaged homologue to allow re-synthesis of the
damaged region [10–13]. BLM helicase physically and
functionally interacts with RAD51 and has been reported
to displace RAD51 from the nucleoprotein filament that is
responsible for homology searching and strand invasion [14,
15]. BLM activity in relation to RAD51 protein depends on
the conformation of the RAD51-ssDNA (single strand
DNA) nucleofilaments which are formed by RAD51 protein
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in presence of RPA protein and ATP. BLM can destabilize
RAD51-ssDNA nucleofilaments if they are in an inactive
form, that is, after joining the ADP. When the RAD51-
ssDNA nucleofilaments are in an active form, after the
ATP joining, BLM stimulates strand exchange carried out
by RAD51 [16, 17].
Loss of RAD51 and BLM proteins may contribute to an
increased number of somatic mutations and rearrangements
of chromosomes. It also contributes to abnormal chromo-
some segregation, aneuploidy, chromosomal instability, sen-
sitivity to DNA damaging agents and loss of heterozygosity.
All the disturbances can lead to reduction of the efficiency
of DNA repair processes, cause genomic instability and
finally lead to the development of cancer [18]. In breast
cancer patients decreasing of the amount of RAD51 protein
was observed in 30 % of the cases [19] whereas loss of
heterozygosity was observed in 32 % of the cases [20]. The
risk of malignant transformation in cells with deficiency of
BLM is a hundred times greater than in cells containing a
fully functional BLM helicase [21]. On the other hand,
different variants of naturally occurring polymorphisms of
genes involved in DNA repair can contribute to changes in
the efficiency of the repair processes, which may result in
the development of cancer [5, 22–27].
The fact that RAD51 and BLM proteins are acting to-
gether during DNA repair by homologous recombination
prompted us to examine a correlation between polymorphic
variants (SNPs) of the RAD51 gene (c.-61 G>T, rs 1801321
and g.38922 C>G, rs 4417527) and the BLM gene (g.96267
A>C, rs 2270132 and g.85394 A>G, rs 2380165) and breast
cancer risk. We also studied an association between these
polymorphisms of the RAD51 and BLM genes and clinical
characteristics of breast cancer patients such as lymph node
status, tumor grade, hormone receptors (estrogen and pro-




Blood samples were obtained from 304 women (mean age
60 years) with sporadic breast cancer treated at the
Department of Surgical Oncology, N. Copernicus Hospital
(Lodz, Poland). The clinical characteristic of breast cancer
patients is presented in Table 1. Blood was collected before
surgical treatment and chemotherapy. The control group
(319 women) consisted of age-matched women who were
not diagnosed with cancer and recruited from Commune
Health Clinic in Rzgow and Institute Polish Mother’s
Health Center (Lodz, Poland). The Local Ethic Committee
approved the study and each patient gave a written consent.
Genomic DNA Isolation
Genomic DNA was prepared from peripheral blood of breast
cancer patients and healthy individuals by using of commercial
Blood Genomic DNA Miniprep Kit (Axygen Biosciences,
CA, USA), as recommended by the manufacturer.
Selection of Polymorphisms and Primers Design
We obtained a list of SNPs in the RAD51 and BLM genes from
the public domain of the National Center for Biotechnology
Information the Single Nucleotide Polymorphisms database
(NCBI dbSNP) at http://www.ncbi.nlm.nih.gov/snp. For this
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study we chose the c.-61 G>T (rs1801321) and g.38922G>C
(rs4417527) polymorphisms of the RAD51 gene and the
g.96267 A>C (rs2270132) and g.85394 A>G (rs2380165)
polymorphisms of the BLM gene with a minor allele frequency
(MAF) 0.467, 0.109, 0.376 and 0.333 in European population,
respectively (submitter population ID: HapMap-CEU for all;
http://www.ncbi.nlm.nih.gov/snp). Primers were designed
according to the published nucleotide sequence in
ENSEMBL database (RAD51 gene ID: ENSG00000051180
and BLM gene ID: ENSG00000197299) and using Primer3
software for c.-61 G>T, g.38922 G>C, g.96267 A>C SNPs
(http://frodo.wi.mit.edu/) and Web-based allele-specific primer
software for g.85394 SNP (http://bioinfo.biotec.or.th/WASP).
Genotype Determination
The restriction fragment length polymorphism reaction (PCR-
RFLP) was used to determine the genotypes of the c.-61 G>T
and the g.38922 C>G polymorphisms of the RAD51 gene and
the g.96267 A>C polymorphism of the BLM gene. The poly-
merase chain reaction with confronting two-pair primers
(PCR-CTPP) was used to determine the genotypes of the
g.85394 A>G polymorphism of the BLM gene.
PCR reaction was performed in a total reaction volume of
25 μl containing 50 ng of genomic DNA, 1 U Biotools
DNA polymerase (Biotools, Madrid, Spain), 1 × reaction
buffer (750 mM Tris-HCl (pH 9.0), 500 mM KCl, 200 mM
(NH4)2SO4), 0.2 mM of each dNTP, 1.5 mM MgCl2 and
0.25 μM of each primer (Metabion, Martinsried, Germany).
The primer sequences are presented in Table 2. PCR ampli-
fications were conducted in DNA Engine thermal cycler
(Bio-Rad Laboratories, Hercules, CA, USA). Thermal cy-
cling conditions were as follows: initial denaturation step at
95 °C for 5 min, 34 cycles at 95 °C for 30 s, 30 s at 65 °C
annealing temperature and 60 s at 72 °C.
The products of the c.-61 G>T and the g.38922 C>G poly-
morphisms of the RAD51 gene and the g.96267 A>C poly-
morphism of the BLM gene were digested overnight with 0.2
U of the restriction enzyme NgoMIV, NlaIII and StyI (NEB
New England Biolabs, Ipswich, MA, USA), respectively. The
PCR products were separated into 8 % polyacrylamide gel,
stained with ethidium bromide and viewed under UV light.
Figure 1 presents a representative gels from analysis of the
c.-61 G>T (A) and the g.38922 C>G (B) polymorphisms
of the RAD51 gene and the g.96267 A>C (C) and the
g.85394 A>G (D) polymorphisms of the BLM gene.
Statistical Analysis
Statistical analysis was performed using STATISTICA8.0 pack-
age (Statsoft, Tulsa, OK, USA). Distributions of genotypes and
alleles between groups were tested using the χ2 analysis. The
Hardy-Weinberg equilibrium was checked using the χ2 test to
compare the observed genotype frequencies with the expected
frequencies among the case and control subjects. For each SNP,
the odds ratios (ORs) and 95 % confidence intervals (CIs) were
calculated. A linkage between genotype, cancer and clinical
parameters was assessed by the logistic regression.
Results
Genotype Analysis
Breast cancer patients and controls were divided into groups
corresponding to three genotypes. The genotype distributions
Table 2 Primer sequences of
the c.-61 G>T and the g.38922
C>G polymorphisms of the
RAD51 gene and the g.96267
A>C and the g.85394 A>G
polymorphisms of the BLM gene
Gene Primer sequences
RAD51 gene
c.-61 G>T; rs 1801321
Sense 5′-TGGGAACTGCAACTCATCTGG-3′
Antisense 5′-GCTCCGACTTCACCCCGCCGG-3′




g.96267 A>C; rs 2270132
Sense 5′-CAGGCTCCCGGATTCTACTC-3′
Antisense 5′-TGTACACCCCCTAGACG-3′
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for the c.-61 G>T and g.38922 C>G polymorphisms of the
RAD51 gene were in agreement with those predicted by the
Hardy-Weinberg equilibrium (p>0.05), except for that of the
c.-61 G>T polymorphism for the patients group. It is
caused by very low presence of the G/G genotype of
the c.-61 G>T polymorphism of the RAD51 gene in the
Polish population. In the case of genotype distributions
for the g.96267 A>C and g.85394 A>G polymorphisms
of the BLM gene they differed significantly from those
predicted by the Hardy-Weinberg equilibrium (p<0.05),
which can be caused by lack of the G/G genotype of
the g.85394 A>G polymorphism and the C/C genotype
of the g.96267 A>C polymorphism of the BLM gene in
the Polish population. The distribution of genotypes of
polymorphic variants of the RAD51 and BLM genes and
intragene and intergene genotypes combinations for can-
cer patients and controls is shown in Table 3.
Clinical Parameters of Breast Cancer Patients and BLM
and RAD51 Genes Polymorphism
We checked the distribution of genotypes and frequency
of alleles of the BLM and RAD51 genes polymorphisms
in groups of patients with different hormone receptor
status, patients with positive and negative lymph node
status and patients with different tumor grade (Table 4).
We did not observe any association between estrogen
hormone receptor status and the distribution of genotypes
and frequency of alleles for four analyzed polymorphisms
(data not shown). We did not observe any association
between HER2 expression and the distribution of geno-
types and frequency of alleles for any polymorphism
(data not shown).
We did not observe any correlation between the g.38922
C>G polymorphism of the RAD51 gene and the g.85394
A>G and the g.96267 A>C polymorphisms of the BLM
gene and lymph node status (data not shown).
Next of the analyzed clinical features was the tumor
grade described by Bloom-Richardson grading system
(Table 4). We did not find any association between the
c.-61 G>T and the g.38922 C>G polymorphisms of the
RAD51 gene and the g.85394 A>G polymorphism of the
BLM gene and tumor grade (data not shown).
Discussion
RAD51 recombinase and BLM helicase are the elements of
the protein machinery performing DNA DSBs repair by
homologous recombination [15]. Homologous recombina-
tion is initiated by the MRN complex (MRE11, RAD50,
NBN) resecting the DSB ends to generate 3′ overhangs
flanking the break site. The resulting ssDNA ends are first
protected by RPA before eventually being coated with
RAD51 protein to form the critical nucleoprotein filament
necessary for accurate repair [11]. BLM helicase was iden-
tified in a large DNA damage surveillance complex with
BRCA1 and MRN complex [28] and has been shown to
associate with many homologous recombination proteins,
such as topoisomerase IIIα, BLAP75/RMI1 and RAD51
[29]. Cell and biochemical studies have led to the view that
BLM has both pro- and anti-recombinogenic functions.
Most notable, BLM is important in stabilizing damaged rep-
lication forks and repressing aberrant recombination events, as
evidenced by the dramatic increase in levels of sister chromatid
exchanges (SCEs) and loss of heterozygosity in BLM null cells.
In contrast, BLM is also predicted to promote homologous
recombination by facilitating exonucleolytic resection of
DSBs, by stimulating synthesis-dependent strand annealing,
and by promoting non-crossover resolution of Holliday
Fig. 1 Genotypes of the c.-61 G>T (rs1801321) (a) and the g.38922
C>G (rs4417527) (b) polymorphisms of the RAD51 gene and the
g.96267 A>C (rs2270132) (c) and the g.85394 A>G (rs2380165) (d)
polymorphisms of the BLM gene analyzed by a 8 % polyacrylamide
gel electrophoresis stained with ethidium bromide and viewed under
UV light. Lane M shows GeneRuler TM 100 bp molecular weight
marker; lane K on the picture C shows a control comprising PCR
product without reaction with StyI restriction enzyme; lane K on the
picture D shows a control comprising reaction mixture with F1 and R1
starters; all remaining lanes present genotypes indicated in the upper
part of the pictures
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Table 3 The genotype and allele frequency and odds ratios (OR) of the c.-61 G>T and the g.38922 C>G polymorphisms of the RAD51 gene and
the g.85394 A>G and the g.96267 A>C polymorphisms of the BLM gene in breast cancer patients and controls
Genotype or allele Breast cancer patients (n=304) Controls (n=319) OR (95 % Cl) p
Number Frequency Number Frequency
RAD51 c.-61 G>T
T/T 139 0.46 260 0.82 0.19 (0.13–0.27)↓ <0.001
T/G 152 0.50 59 0.18 4.41 (3.07–6.32)↑ <0.001
G/G 13 0.04 0 0 – –
T 430 0.71 579 0.91 0.20 (0.14–0.28)↓ <0.001
RAD51 g.38922 C>G
C/C 217 0.71 250 0.78 0.69 (0.48–0.99)↓ 0.045
C/G 83 0.27 65 0.20 1.47 (1.01–2.13)↑ 0.043
G/G 4 0.01 4 0.01 1.05 (0.26–4.24) 0.945
C 517 0.85 565 0.89 0.72 (0.52–1.02) 0.061
BLM g.85394 A>G
A/A 231 0.76 208 0.65 1.69 (1.19–2.40)↑ 0.003
A/G 73 0.24 111 0.35 0.59 (0.42–0.84)↓ 0.003
G/G 0 0 0 0 – –
A 535 0.88 527 0.83 1.54 (1.12–2.12)↑ 0.003
BLM g.96267 A>C
A/A 55 0.18 26 0.08 2.49 (1.52–4.09)↑ <0.001
A/C 249 0.82 293 0.92 0.40 (0.25–0.66)↓ <0.001
C/C 0 0 0 0 – –
A 359 0.59 345 0.54 1.22 (0.97–1.53)↑ <0.001
RAD51 (c.-61 G>T and
g.38922 C>G)
TT/CC 105 0.35 207 0.65 0.29 (0.21–0.40)↓ <0.001
TT/CG 33 0.11 51 0.16 0.64 (0.40–1.02) 0.062
TG/CC 104 0.34 43 0.13 3.34 (2.24–4.98)↑ <0.001
TG/CG 45 0.15 14 0.04 3.79 (2.03–7.05)↑ <0.001
BLM (g.85394 A>G and
g.96267 A>C)
AA/AA 43 0.15 20 0.05 2.46 (1.41–4.29)↑ 0.001
AA/AC 188 0.62 188 0.59 1.13 (0.82–1.56) 0.458
AG/AC 61 0.20 105 0.33 0.51 (0.36–0.74) ↓ <0.001
RAD51 (c.-61 G>T) and
BLM (g.96267 A>C)
TT/AA 23 0.08 22 0.07 1.11 (0.60–2.03) 0.747
TT/AC 116 0.38 238 0.75 0.21 (0.15–0.30)↓ <0.001
TG/AA 29 0.10 4 0.01 8.31 (2.88–23.92)↑ <0.001
TG/AC 123 0.40 55 0.17 3.26 (2.25–4.72)↑ <0.001
RAD51 (c.-61 G>T) and
BLM (g.85394 A>G)
TT/AA 101 0.33 173 0.54 0.42 (0.30–0.58)↓ <0.001
TT/AG 38 0.13 87 0.27 0.38 (0.25–0.58)↓ <0.001
TG/AA 120 0.39 35 0.11 5.29 (3.48–8.05)↑ <0.001
TG/AG 32 0.11 24 0.08 1.45 (0.83–2.52) 0.192
RAD51 (g.38922 C>G) and
BLM (g.96267 A>C)
GG/AA 32 0.11 19 0.06 1.86 (1.03–3.35)↑ 0.040
GG/AC 185 0.61 231 0.72 0.59 (0.42–0.83)↓ 0.002
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junctions [30]. Recently, it was shown that SUMOylation of
BLM can affect its interactions with RAD51. SUMOylation of
BLM facilitates repair of damaged replication forks by homol-
ogous recombination by modulating recruitment of RAD51 or
retention at repair sites [31].
Defects in some DNA repair genes are associated with rare
human cancer-prone disorders, like Bloom syndrome resulting
from a mutation of the BLM gene, ataxia telangiectasia and
Werner syndrom. Apart from these rare syndromes, deficient
DNA repair is suggested as a predisposing factor in familial
breast cancer and in some sporadic breast cancers [3–6].
Advances in the understating of genetic predispositions to
breast cancer have also been made by screening naturally
occurring polymorphisms in DNA repair genes [5, 22–27].
These studies revealed that subtle defects in DNA repair capac-
ity arising from low-penetrance genes or their combinations are
modified by other genetically determined or environmental
factors and correlate to breast cancer risk.
In the present study we correlated the genetic constitution of
breast cancer patients expressed by polymorphic variants of
two important homologous recombination genes, BLM and
RAD51, with clinical parameters of patients, including lymph
node status, tumor grade, hormone receptors (estrogen and
progesterone receptors) and epidermal growth factor receptor
2 (HER2) expression. The c.-61 G>T-RAD51 polymorphism is
located in the 5′-untranslated region, the regulatory promoter
element of the RAD51 gene. It could affect translation efficien-
cy and mRNA stability, leading to changes in RAD51 protein
Table 3 (continued)
Genotype or allele Breast cancer patients (n=304) Controls (n=319) OR (95% Cl) p
Number Frequency Number Frequency
GC/AA 22 0.07 7 0.02 3.48 (1.46–8.26)↑ 0.005
GC/AC 61 0.20 58 0.18 1.13 (0.76–1.69) 0.550
RAD51 (g.38922 C>G) and
BLM (g.85394 A>G)
GG/AA 163 0.54 160 0.50 1.15 (0.84–1.57) 0.387
GG/AG 54 0.18 90 0.28 0.55 (0.38–0.81)↓ 0.002
GC/AA 65 0.21 46 0.14 1.61 (1.07–2.45)↑ 0.024
GC/AG 18 0.06 19 0.06 0.99 (0.51–1.93) 0.985
Table 4 The genotype, allele frequency and odds ratios (OR) of the c.-61 G>T polymorphism of the RAD51 gene and the g.96267 A>C
polymorphism of the BLM gene in subjects with breast cancer with different clinical parameters
Genotype or allele PR receptor negative (n=94) PR receptor positive (n=167) OR (95 % Cl) p
Number Frequency Number Frequency
RAD51 gene (c.-61 G>T)
T/T 47 0.50 66 0.40 1.53 (0.91–2.55) 0.102
T/G 41 0.44 96 0.57 0.57 (0.34–0.95)↓ 0.032
G/G 6 0.06 5 0.03 2.21 (0.66–7.44) 0.201
T 135 0.72 228 0.68 1.25 (0.80–1.96) 0.333
Genotype or allele Node positive (n=89) Node negative (n=114) OR (95 % Cl) p
Number Frequency Number Frequency
RAD51 gene (c.-61 G>T)
T/T 32 0.36 57 0.50 0.56 (0.32–0.99)↓ 0.046
T/G 55 0.62 53 0.46 1.86 (1.06–3.27)↑ 0.031
T 119 0.67 167 0.73 0.65 (0.39–1.09) 0.101
Genotype or allele G3 positive (n=95) G3 negative (n=104) OR (95 % Cl) p
Number Frequency Number Frequency
BLM gene (g.96267 A>C)
A/A 23 0.24 12 0.12 2.45 (1.14–5.25)↑ 0.021
A/C 72 0.76 92 0.88 0.41 (0.19–0.88)↓ 0.021
A 118 0.62 116 0.56 1.30 (0.87–1.94) 0.200
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levels, which, in turn, could influence on the activity of the
multiprotein DNA-repair complex that includes BRCA1,
BRCA2 and RAD51, and leads to breast cancer susceptibility.
The g.38922 C>G-RAD51 polymorphism is located in the
intron 10 in the RAD51 gene. The intron 10 is located between
the exons in the core conserved domain that includes Walker
A and B motifs, which have the function of ATP binding and
hydrolysis activities. Because of the intron localization the
g.38922 C>G polymorphism does not affect amino acid cod-
ing and therefore probably does not directly affect protein
function but it is likely that may play a role in the proper
recognition of non-coding element of RNA splicing and thus
it may be indirectly responsible for the correct functioning of
RAD51 protein. In turn, it could influence the activity of the
multiprotein DNA-repair complex that includes BRCA1,
BRCA2, RAD51 and other proteins. On the other hand, the
observed associations between breast cancer risk and the
g.38922 C>G-RAD51 polymorphism can be interpreted as
affecting the mRNA maturation process and in consequence
activity of RAD51 protein.
Beyond genotypes, the expression of genes or proteins
might also play a role in breast cancer risk. RAD51 over-
expression was associated with a higher risk of locoregional
recurrence and death. RAD51 overexpression was also signif-
icantly associated with shorter locoregional recurrence-free
survival and overall survival [32]. Moreover, it was shown,
that RAD51 mRNA levels were inversely associated with PR
status and the highest levels were detected in ER-positive/PR-
negative tumors. The analysis of microarray expression data
from 295 breast cancers indicate that RAD51 increased
mRNA expression is associated with higher risk of tumor
relapse, distant metastases and worst overall survival [33].
The g.96267 A>C polymorphism is located in the intron 20
and the g.85394 A>G polymorphism is located in the intron 17
of the BLM gene. These introns separate exons forming the
evolutionarily preserved RecQ-like domain. This domain
exhibits a high degree of homology with the RecQ protein of
E. coli. RecQ-like domain and its constituent sub-domains are
responsible for the most important functions of BLM helicase
[34]. The polymorphic variant g.96267 A>C is located in the
intron 20, which separates the exons encoding the HRDC
domain (helicase and RNase D-like C-terminal domain),
which in RecQ family-like helicases plays the role in recog-
nizing and binding substrates and protein-protein interactions.
In the case of BLM helicase, HRDC domain is also involved in
the process of movement and developing of the Holliday
structure. Therefore, it is likely that the polymorphic variants
of the BLM gene g.96267 A>C and g.85394 A>Gmay play an
important role in the proper recognition and cutting out introns
in the process of mRNAmaturation andmay be responsible for
the correct functioning of BLM helicase.
Our results on the genes polymorphism and breast cancer
risk are partly in agreement with the study presented by
Ding et al. [26]. Comparing the results of Ding et al. carried
out on population of women living in Taiwan to our results
we simillarly observed a protective role of the A/C variant in
the case of the g.96267 A>C polymorphism of the BLM
gene (Table 3). On the other hand, our results disagree with
those of Ding et al. in the case of the genotype the C/C of the
g.38922 C>G polymorphism of the RAD51 gene (Table 3).
It was shown that the polymorphic variant of the BLM
gene − rs2380165 and the variants of the RAD51 gene –
rs4417527 and rs2412546 were associated with breast can-
cer risk [26]. Moreover, not only the intronic polymorphisms
located within the region encoding the helicase domain of
BLM but also these within the RAD51-interaction domain-
encoding region showed an interaction with RAD51 polymor-
phisms in determining breast cancer susceptibility. Recently, it
was also shown that the domains responsible for RAD51
partnership coincide with the domains responsible for the
binding of ssDNA, BLM100–214 and BLM1317–1367 [29]. This
suggests that the ability of BLM to suppress homologous
recombination may involve both the displacement of
RAD51 from the D-loop and the binding of BLM to the newly
liberated ssDNA to reinstate the duplex and completely im-
pede genetic exchange through homologous recombination.
In the present study we also correlated the genotype
combinations of four polymorphic variants of the BLM and
RAD51 genes with breast cancer occurrence (Table 3).
Especially, in the case of analysis of genotype intergene
combinations and breast cancer occurrence, we detected a
high increase of cancer risk (Table 3).
Relationship between the c.-61 G>T and g.38922 C>G
polymorphisms of the RAD51 gene, and the g.91266 C>A
and g.85394 A>G polymorphisms of the BLM gene and
clinical characteristics of breast cancer patients was also stud-
ied (Table 4). Breast cancer patients were divided into groups
depending on lymph node status, tumor grade and expression
of estrogen and progesterone receptors (ER and PR) and
HER2 receptor status. Auxiliary lymph node status and tumor
size are clinical parameters directly correlated with the surviv-
al period in breast cancer. Expression level of ER and PR are
useful predictive markers allowing the assessment of the
response to endocrine therapy – ER- and PR-positive tumors
may have a 6- to 7-higher response rate to negatives [35].
Next of the analyzed clinical features was the presence of
HER2 (C-ERB/neu), belonging to the group of oncogenes
of the tyrosine kinase function, which is overexpressed in
about 20–30 % of breast cancers and often is associated with
the resistance to a hormone therapy. Activation of this
receptor leads to the uncontrolled division of cancer cells,
which may be accompanied by an increased amount of
vascular endothelial growth factor (VEGF) as the main
factor inducing the formation of new blood vessels within
the tumor. HER2 overexpression leads to early metastases in
the direction of the lymph nodes, early recurrences of the
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disease and is associated with shorter survival and worse
clinical prognosis [36]. We did not observe any association
between HER2 expression and the distribution of genotypes
and frequency of alleles within any of the analyzed poly-
morphisms (data not shown).
We also correlated the genotypes of the BLM and RAD51
polymorphic variants with tumor grade described by the
Bloom-Richardson grading system (Table 4). It is a three-
step scale, according to which the tumor samples taken
during biopsy are classified, and then analyzed using a
microscope. To the G1 category belong tumors whose cells
are small, have regular shapes, show high similarity in
structural terms to normal breast cells and their mitotic index
does not exceed the number of seventh. To the G2 category
belong tumors whose cells exhibit visible changes compared
to normal breast cells and their mitotic index ranges from
8 to 14. To the last G3 category belong tumors whose cells
are large and have irregular shapes. They differ significantly
from normal cells, divide rapidly − their mitotic index
exceeds the number 15.
The results obtained indicate that the RAD51 and BLM
genes polymorphism can be associated with breast cancer
risk. An association may be underlined by a common inter-
action between these genes. We showed that the c.-61 G>T
polymorphism of the RAD51 gene might modulate breast
cancer risk and be associated with progesterone receptor
expression and local metastasis. We also found an associa-
tion between the g.96267 A>C-BLM polymorphism and G3
grade of tumor.
Conclusion
The variability of the RAD51 and BLM genes may play a
role in breast cancer occurrence. The examined polymor-
phisms of the RAD51 and BLM genes cannot be an inde-
pendent markers of breast cancer but our studies may be
useful in building a set of clinical and molecular markers
helpful for diagnosis of breast cancer.
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